TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody
2023-06-16
免疫疗法临床1期临床申请
HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. The antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and remarkable druggability.
TGI-6's TAA is highly expressed in various solid tumors, including colorectal cancer, breast cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, pancreatic cancer, and more. This makes TGI-6 a promising candidate for the treatment of a wide range of solid tumors. Preclinical studies have shown outstanding potential, with TGI-6 inducing complete tumor regression in animal models of colorectal cancer following a single administration. Importantly, TGI-6 is designed to maintain high cytotoxic activity while minimizing the risk of cytokine release syndrome (CRS).
"We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said Professor Zhigang Tian, founder of TGI and member of the Chinese Academy of Engineering and the Academia Europaea. "TGI-6 has demonstrated superior anti-tumor activity and safety in preclinical studies. We have great confidence in its potential as a novel therapy for solid tumors."
With this significant milestone, TGI is actively seeking global partners to collaborate on the development, clinical trials, and eventual commercialization of TGI-6. By partnering with pharmaceutical and biotechnology companies, TGI aims to leverage their expertise in clinical development and market access, expediting the availability of TGI-6 for patients worldwide.
TGI remains steadfast in its mission to revolutionize cancer treatment through innovative immunotherapies. With FDA clearance for the clinical trial of TGI-6, the company is poised to advance the development of precise therapies for solid tumors. Interested parties are invited to explore partnership opportunities and join TGI in their pursuit of delivering novel treatment options that improve patient outcomes.
About TG ImmunoPharma Co., Ltd. (TGI)
TG ImmunoPharma Co., Ltd. (TGI) is a leading biotech company dedicated to the development of novel immunotherapeutic drugs. Focusing on innovation and research, TGITGI harnesses the power of the immune system to combat cancer and enhance patient outcomes. The company's diverse pipeline includes bispecific antibodies, immune checkpoint inhibitors, NK/T-cell engagers, and immunocytokines. TGI has successfully developed over 10 pipeline products, with more than half having completed pre-clinical studies. Notably, TGI-2, an anti-PVRIG therapeutic antibody, has initiated Phase 1 trials in the United States and is nearing completion of its first patient dosing. TGI envisions three innovative drugs entering Phase I trials by the end of next year, demonstrating its commitment to advancing immunotherapy and addressing unmet needs in cancer treatment worldwide. To learn more about TGI and its pipeline, please visit www.tgimmunopharma.com.
For further information or partnership inquiries, please contact:
Dr. SUN Haoyu,
Head of Operation, TG ImmunoPharma
[email protected]
SOURCE TG ImmunoPharma Co., Ltd.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。